Meet the Experts: Cyclodextrins as active ingredients in the 21st century – Webinar of CycloLab
After the great success of the webinar held in May, 2021 a next webinar organized by CycloLab will be held
Meet the Experts: Cyclodextrins as active ingredients in the 21st century – Webinar of CycloLab
After the great success of the webinar held in May, 2021 a next webinar organized by CycloLab will be held
Novel β-cyclodextrin Polyurethane Materials with Antibiotic Activity
Novel quaternary ammonium salt functionalized β-cyclodextrin polyurethane (QAS-β-CDPU) microparticles were successfully constructed . By adjusting the proportion of the chlorine-containing
Updates on development of oral remdesivir formulations
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
Marinus Announces FDA Acceptance for Filing and Priority Review of NDA for SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that
Sugammadex, the Guardian of Deep Muscle Relaxation During Conventional and Robot-Assisted Laparoscopic Surgery: A Narrative Review.
High intra-abdominal pressure induced by artificial pneumoperitoneum can obviously impair respiratory and circulatory functions and has a negative effect on
Harvard scientists discover the prophylactic effect of SBECD solubilized amodiaquine against SARS-CoV2 infection
Amodiaquine is a commonly used medicament for the treatment of malarial infections. It is a 4-aminoquinoline compound similar to chloroquine
10th Annual International Symposium of Drug Delivery Systems – 2022 (SDDS-2022)
The 9th Annual International Symposium of Drug Delivery Systems – 2022 (SDDS-2022) will take place during May 11-13, 2022 in Tokyo, Japan. Confirmed
Large ring cyclodextrins for solubilization of Domperidone
Large ring cyclodextrins were prepared and studied as alternatives for drug solubilization [1]. A mixture of CD22-48 was compared with
Cyclodextrin-based supramolecular low melting mixtures: efficient absorbents for volatile organic compounds abatement
Cyclodextrins (CDs) and deep eutectic solvents (DESs) are emerging absorbent materials for the removal of volatile organic compounds (VOCs). DESs
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced